Search

Your search keyword '"Furumoto, Shozo"' showing total 198 results
Start Over Author "Furumoto, Shozo" Search Limiters Full Text
198 results on '"Furumoto, Shozo"'

2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Author

Toyohara, Jun, Al-Qahtani, Mohammed, Huang, Ya-Yao, Cazzola, Emiliano, Todde, Sergio, Furumoto, Shozo, Mikolajczak, Renata, Decristoforo, Clemens, Gillings, Nic, Yang, Min, Reilly, Raymond, Duatti, Adriano, Denkova, Antonia, Schirrmacher, Ralf, Carlucci, Giuseppe, Seimbille, Yann, Liu, Zhaofei, Ellis, Beverley, Cornelissen, Bart, Kopka, Klaus, and Bernardes, Emerson

Subjects
Highlight Articles, Nuclear Medicine, Radiochemistry, Radiopharmaceutical Sciences, Radiopharmacy, Trends in Radiopharmaceutical Sciences
Abstract

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry.

Published
2022

3. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Author

Bernardes, Emerson, Caravan, Peter, van Dam, Michael, Deuther-Conrad, Winnie, Ellis, Beverley, Furumoto, Shozo, Guillet, Benjamin, Huang, Ya-Yao, Jia, Hongmei, Laverman, Peter, Li, Zijing, Liu, Zhaofei, Lodi, Filippo, Miao, Yubin, Perk, Lars, Schirrmacher, Ralf, Vercoullie, Johnny, Yang, Hua, Yang, Min, Yang, Xing, Zhang, Junbo, Zhang, Ming-Rong, and Zhu, Hua

Subjects
Highlights, Radiochemistry, Radiopharmacy, Review
Abstract

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. RESULTS: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included. CONCLUSION: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Published
2022

5. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351

Author

Lockhart, Samuel N, Baker, Suzanne L, Okamura, Nobuyuki, Furukawa, Katsutoshi, Ishiki, Aiko, Furumoto, Shozo, Tashiro, Manabu, Yanai, Kazuhiko, Arai, Hiroyuki, Kudo, Yukitsuka, Harada, Ryuichi, Tomita, Naoki, Hiraoka, Kotaro, Watanuki, Shoichi, and Jagust, William J

Subjects
Biological Psychology, Psychology, Biomedical Imaging, Dementia, Neurosciences, Clinical Research, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Alzheimer's Disease, Aging, Neurodegenerative, Brain Disorders, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Neurological, Aged, Alzheimer Disease, Aminopyridines, Biomarkers, Brain, Brain Mapping, Case-Control Studies, Cognition, Fluorine Radioisotopes, Frontal Lobe, Humans, Positron-Emission Tomography, Quinolines, Temporal Lobe, Time Factors, tau Proteins, General Science & Technology
Abstract

Background[18F]THK5351, a recently-developed positron emission tomography (PET) tracer for measuring tau neurofibrillary tangle accumulation, may help researchers examine aging, disease, and tau pathology in living human brains. We examined THK5351 tracer pharmacokinetics to define an optimal acquisition time for static late images.MethodsPrimary measurements were calculation of regional values of distribution volume ratios (DVR) and standardized uptake value ratios (SUVR) in 6 healthy older control and 10 Alzheimer's disease (AD) participants. We examined associations between DVR and SUVR, searching for a 20 min SUVR time window that was stable and comparable to DVR. We additionally examined diagnostic group differences in this 20 min SUVR.ResultsIn healthy controls, [18F]THK5351 uptake was low, with increased temporal relative to frontal binding. In AD, regional uptake was substantially higher than in healthy controls, with temporal exceeding frontal binding. Retention in cerebellar gray matter, which was used as the reference region, was low compared to other regions. Both DVR and SUVR values showed minimal change over time after 40 min. SUVR 20-40, 30-50, and 40-60 min were most consistently correlated with DVR; SUVR 40-60 min, the most stable time window, was used in further analyses. Significant (AD > healthy control) group differences existed in temporoparietal regions, with marginal medial temporal differences. We found high basal ganglia SUVR 40-60 min signal, with no group differences.ConclusionsWe examined THK5351, a new PET tracer for measuring tau accumulation, and compared multiple analysis methods for quantifying regional tracer uptake. SUVR 40-60 min performed optimally when examining 20 min SUVR windows, and appears to be a practical method for quantifying relative regional tracer retention. The results of this study offer clinical potential, given the usefulness of THK5351-PET as a biomarker of tau pathology in aging and disease.

Published
2016

7. The neuromodulatory role of dopamine in improved reaction time by acute cardiovascular exercise

Author

Ando, Soichi, primary, Fujimoto, Toshihiko, additional, Sudo, Mizuki, additional, Watanuki, Shoichi, additional, Hiraoka, Kotaro, additional, Takeda, Kazuko, additional, Takagi, Yoko, additional, Kitajima, Daisuke, additional, Mochizuki, Kodai, additional, Matsuura, Koki, additional, Katagiri, Yuki, additional, Nasir, Fairuz Mohd, additional, Lin, Yuchen, additional, Fujibayashi, Mami, additional, Costello, Joseph T., additional, McMorris, Terry, additional, Ishikawa, Yoichi, additional, Funaki, Yoshihito, additional, Furumoto, Shozo, additional, Watabe, Hiroshi, additional, and Tashiro, Manabu, additional

Published
2024
Full Text
View/download PDF

13. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

Author

Maruyama, Masahiro, Shimada, Hitoshi, Suhara, Tetsuya, Shinotoh, Hitoshi, Ji, Bin, Maeda, Jun, Zhang, Ming-Rong, Trojanowski, John Q., Lee, Virginia M.-Y., Ono, Maiko, Masamoto, Kazuto, Takano, Harumasa, Sahara, Naruhiko, Iwata, Nobuhisa, Okamura, Nobuyuki, Furumoto, Shozo, Kudo, Yukitsuka, Chang, Qing, Saido, Takaomi C., Takashima, Akihiko, Lewis, Jada, Jang, Ming-Kuei, Aoki, Ichio, Ito, Hiroshi, and Higuchi, Makoto

Published
2013
Full Text
View/download PDF

14. Evaluation of 18F labeled glial fibrillary acidic protein binding nanobody and its brain shuttle peptide fusion proteins using a neuroinflammation rat model.

Author

Morito, Takahiro, Harada, Ryuichi, Iwata, Ren, Ishikawa, Yoichi, Okamura, Nobuyuki, Kudo, Yukitsuka, Furumoto, Shozo, Yanai, Kazuhiko, and Tashiro, Manabu

Subjects
GLIAL fibrillary acidic protein, CHIMERIC proteins, PEPTIDES, TRANSLOCATOR proteins, PROTEIN binding, ANIMAL disease models
Abstract

Astrogliosis is a crucial feature of neuroinflammation and is characterized by the significant upregulation of glial fibrillary acidic protein (GFAP) expression. Hence, visualizing GFAP in the living brain of patients with damaged central nervous system using positron emission tomography (PET) is of great importance, and it is expected to depict neuroinflammation more directly than existing neuroinflammation imaging markers. However, no PET radiotracers for GFAP are currently available. Therefore, neuroimaging with antibody-like affinity proteins could be a viable strategy for visualizing imaging targets that small molecules rarely recognize, such as GFAP, while we need to overcome the challenges of slow clearance and low brain permeability. The E9 nanobody, a small-affinity protein with high affinity and selectivity for GFAP, was utilized in this study. E9 was engineered by fusing a brain shuttle peptide that facilitates blood-brain barrier permeation via two different types of linker domains: E9-GS-ApoE (EGA) and E9-EAK-ApoE (EEA). E9, EGA and EEA were radiolabeled with fluorine-18 using cell-free protein radiosynthesis. In vitro autoradiography showed that all radiolabeled proteins exhibited a significant difference in neuroinflammation in the brain sections created from a rat model constructed by injecting lipopolysaccharide (LPS) into the unilateral striatum of wildtype rats, and an excess competitor displaced their binding. However, exploratory in vivo PET imaging and ex vivo biodistribution studies in the rat model failed to distinguish neuroinflammatory lesions within 3 h of 18F-EEA intravenous injection. This study contributes to a better understanding of the characteristics of small-affinity proteins fused with a brain shuttle peptide for further research into the use of protein molecules as PET tracers for imaging neuropathology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Author

Toyohara, Jun (author), Al-Qahtani, Mohammed (author), Huang, Ya Yao (author), Cazzola, Emiliano (author), Todde, Sergio (author), Furumoto, Shozo (author), Mikolajczak, Renata (author), Denkova, A.G. (author), Seimbille, Y. (author), Toyohara, Jun (author), Al-Qahtani, Mohammed (author), Huang, Ya Yao (author), Cazzola, Emiliano (author), Todde, Sergio (author), Furumoto, Shozo (author), Mikolajczak, Renata (author), Denkova, A.G. (author), and Seimbille, Y. (author)

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main Body: This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Conclusion: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry., RST/Applied Radiation & Isotopes

Published
2022
Full Text
View/download PDF

17. First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis

Author

Villemagne, Victor L., primary, Harada, Ryuichi, additional, Doré, Vincent, additional, Furumoto, Shozo, additional, Mulligan, Rachel, additional, Kudo, Yukitsuka, additional, Burnham, Samantha, additional, Krishnadas, Natasha, additional, Bozinovski, Svetlana, additional, Huang, Kun, additional, Lopresti, Brian J., additional, Yanai, Kazuhiko, additional, Rowe, Christopher C., additional, and Okamura, Nobuyuki, additional

Published
2022
Full Text
View/download PDF

18. Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum

Author

Villemagne, Victor L., primary, Harada, Ryuichi, additional, Doré, Vincent, additional, Furumoto, Shozo, additional, Mulligan, Rachel, additional, Kudo, Yukitsuka, additional, Burnham, Samantha, additional, Krishnadas, Natasha, additional, Bourgeat, Pierrick, additional, Xia, Ying, additional, Laws, Simon, additional, Bozinovski, Svetlana, additional, Huang, Kun, additional, Ikonomovic, Milos D., additional, Fripp, Jürgen, additional, Yanai, Kazuhiko, additional, Okamura, Nobuyuki, additional, and Rowe, Christopher C., additional

Published
2022
Full Text
View/download PDF

19. 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Author

Ezura, Michinori, primary, Kikuchi, Akio, additional, Okamura, Nobuyuki, additional, Ishiki, Aiko, additional, Hasegawa, Takafumi, additional, Harada, Ryuichi, additional, Watanuki, Shoichi, additional, Funaki, Yoshihito, additional, Hiraoka, Kotaro, additional, Baba, Toru, additional, Sugeno, Naoto, additional, Yoshida, Shun, additional, Kobayashi, Junpei, additional, Kobayashi, Michiko, additional, Tano, Ohito, additional, Ishiyama, Shun, additional, Nakamura, Takaaki, additional, Nakashima, Ichiro, additional, Mugikura, Shunji, additional, Iwata, Ren, additional, Taki, Yasuyuki, additional, Furukawa, Katsutoshi, additional, Arai, Hiroyuki, additional, Furumoto, Shozo, additional, Tashiro, Manabu, additional, Yanai, Kazuhiko, additional, Kudo, Yukitsuka, additional, Takeda, Atsushi, additional, and Aoki, Masashi, additional

Published
2021
Full Text
View/download PDF

21. Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer

Author

Shindo, Haruhiko, primary, Harada-Shoji, Narumi, additional, Ebata, Akiko, additional, Sato, Miku, additional, Soga, Tomoyoshi, additional, Miyashita, Minoru, additional, Tada, Hiroshi, additional, Kawai, Masaaki, additional, Kosaka, Shinkichi, additional, Onuki, Koji, additional, Usami, Shin, additional, Furumoto, Shozo, additional, Hayashi, Shinichi, additional, Abe, Takaaki, additional, Suzuki, Takashi, additional, Ishida, Takanori, additional, and Sasano, Hironobu, additional

Published
2021
Full Text
View/download PDF

30. The challenges of tau imaging

Author

Villemagne, Victor L, Furumoto, Shozo, Fodero-Tavoletti, Michelle, Harada, Ryuichi, Mulligan, Rachel S, Kudo, Yukitsuka, Masters, Colin L, Yanai, Kazuhiko, Rowe, Chistopher C, and Okamura, Nobuyuki

Published
2012
Full Text
View/download PDF

31. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease

Author

Fodero-Tavoletti, Michelle T., Okamura, Nobuyuki, Furumoto, Shozo, Mulligan, Rachel S., Connor, Andrea R., McLean, Catriona A., Cao, Diana, Rigopoulos, Angela, Cartwright, Glenn A., O’Keefe, Graeme, Gong, Sylvia, Adlard, Paul A., Barnham, Kevin J., Rowe, Christopher C., Masters, Colin L., Kudo, Yukitsuka, Cappai, Roberto, Yanai, Kazuhiko, and Villemagne, Victor L.

Published
2011
Full Text
View/download PDF

32. Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle

Author

Liu, Jing, primary, Peng, Yunhua, additional, Shi, Le, additional, Wan, Lixin, additional, Inuzuka, Hiroyuki, additional, Long, Jiangang, additional, Guo, Jianping, additional, Zhang, Jinfang, additional, Yuan, Min, additional, Zhang, Shuangxi, additional, Wang, Xun, additional, Gao, Jing, additional, Dai, Xiangpeng, additional, Furumoto, Shozo, additional, Jia, Lijun, additional, Pandolfi, Pier Paolo, additional, Asara, John M., additional, Kaelin, William G., additional, Liu, Jiankang, additional, and Wei, Wenyi, additional

Published
2020
Full Text
View/download PDF

33. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle

Author

Liu, Jing, primary, Peng, Yunhua, additional, Shi, Le, additional, Wan, Lixin, additional, Inuzuka, Hiroyuki, additional, Long, Jiangang, additional, Guo, Jianping, additional, Zhang, Jinfang, additional, Yuan, Min, additional, Zhang, Shuangxi, additional, Wang, Xun, additional, Gao, Jing, additional, Dai, Xiangpeng, additional, Furumoto, Shozo, additional, Jia, Lijun, additional, Pandolfi, Pier Paolo, additional, Asara, John M., additional, Kaelin, William G., additional, Liu, Jiankang, additional, and Wei, Wenyi, additional

Published
2020
Full Text
View/download PDF

34. 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging

Author

Harada, Ryuichi, primary, Hayakawa, Yoshimi, additional, Ezura, Michinori, additional, Lerdsirisuk, Pradith, additional, Du, Yiqing, additional, Ishikawa, Yoichi, additional, Iwata, Ren, additional, Shidahara, Miho, additional, Ishiki, Aiko, additional, Kikuchi, Akio, additional, Arai, Hiroyuki, additional, Kudo, Yukitsuka, additional, Yanai, Kazuhiko, additional, Furumoto, Shozo, additional, and Okamura, Nobuyuki, additional

Published
2020
Full Text
View/download PDF

35. In vivo visualization of α-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy

Author

Kikuchi, Akio, Takeda, Atsushi, Okamura, Nobuyuki, Tashiro, Manabu, Hasegawa, Takafumi, Furumoto, Shozo, Kobayashi, Michiko, Sugeno, Naoto, Baba, Toru, Miki, Yasuo, Mori, Fumiaki, Wakabayashi, Koichi, Funaki, Yoshihito, Iwata, Ren, Takahashi, Shoki, Fukuda, Hiroshi, Arai, Hiroyuki, Kudo, Yukitsuka, Yanai, Kazuhiko, and Itoyama, Yasuto

Published
2010
Full Text
View/download PDF

40. Current abstracts of the articles published in The Japanese Journal of Nuclear Medicine

Author

Ishikawa, Yoichi, Funakj, Yoshihito, Iwata, Ren, Furumoto, Shozo, Nakata, Eiko, Kudo, Yukitsuka, Kaneta, Tomohiro, Hakamatsuka, Takashi, Takai, Yoshihiro, Yamada, Shogo, Takaki, Akihiro, Yoshioka, Katsunori, Teraoka, Satomi, Souma, Tsutomu, Okada, Kazuhiro, Yokoi, Takashi, Murase, Kenya, Mori, Yutaka, Kusakabe, Kiyoko, Ikekubo, Katsuji, Ishikawa, Naofumi, Nakada, Kunihiro, Kanaya, Shinichi, Misaki, Takashi, Yokoyama, Kunihiko, Kubo, Atsushi, Higashi, Tatsuya, Itou, Kouichi, Noguchi, Yasushi, Tsuchimochi, Shinsaku, and Togawa, Takashi

Published
2005
Full Text
View/download PDF

41. Additional file 1: of Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy

Author

Ishiki, Aiko, Harada, Ryuichi, Kai, Hideaki, Sato, Naomi, Totsune, Tomoko, Tomita, Naoki, Watanuki, Shoichi, Hiraoka, Kotaro, Ishikawa, Yoichi, Funaki, Yoshihito, Iwata, Ren, Furumoto, Shozo, Tashiro, Manabu, Sasano, Hironobu, Tetsuyuki Kitamoto, Yukitsuka Kudo, Yanai, Kazuhiko, Furukawa, Katsutoshi, Okamura, Nobuyuki, and Arai, Hiroyuki

Subjects
mental disorders
Abstract

Figure S1. Immunoblot analysis of sarkosyl-insoluble tau in the study subject and an AD case detected by T46 (anti-tau C-terminus). The study subjects contained dominantly 4R tau (64- and 68-kDa tau). (PPTX 334 kb)

Published
2018
Full Text
View/download PDF

43. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients

Author

Shigemoto, Yoko, primary, Sone, Daichi, additional, Maikusa, Norihide, additional, Okamura, Nobuyuki, additional, Furumoto, Shozo, additional, Kudo, Yukitsuka, additional, Ogawa, Masayo, additional, Takano, Harumasa, additional, Yokoi, Yuma, additional, Sakata, Masuhiro, additional, Tsukamoto, Tadashi, additional, Kato, Koichi, additional, Sato, Noriko, additional, and Matsuda, Hiroshi, additional

Published
2018
Full Text
View/download PDF

46. Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer’s Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study

Author

Shigemoto, Yoko, primary, Sone, Daichi, additional, Imabayashi, Etsuko, additional, Maikusa, Norihide, additional, Okamura, Nobuyuki, additional, Furumoto, Shozo, additional, Kudo, Yukitsuka, additional, Ogawa, Masayo, additional, Takano, Harumasa, additional, Yokoi, Yuma, additional, Sakata, Masuhiro, additional, Tsukamoto, Tadashi, additional, Kato, Koichi, additional, Sato, Noriko, additional, and Matsuda, Hiroshi, additional

Published
2018
Full Text
View/download PDF

47. Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease

Author

Harada, Ryuichi, primary, Ishiki, Aiko, additional, Kai, Hideaki, additional, Sato, Naomi, additional, Furukawa, Katsutoshi, additional, Furumoto, Shozo, additional, Tago, Tetsuro, additional, Tomita, Naoki, additional, Watanuki, Shoichi, additional, Hiraoka, Kotaro, additional, Ishikawa, Yoichi, additional, Funaki, Yoshihito, additional, Nakamura, Tadaho, additional, Yoshikawa, Takeo, additional, Iwata, Ren, additional, Tashiro, Manabu, additional, Sasano, Hironobu, additional, Kitamoto, Tetsuyuki, additional, Yanai, Kazuhiko, additional, Arai, Hiroyuki, additional, Kudo, Yukitsuka, additional, and Okamura, Nobuyuki, additional

Published
2017
Full Text
View/download PDF

48. Development of [C-11]/[H-3-1]THK-5351-A potential novel carbon-11 tau imaging PET radioligand

Author

Stepanov, Vladimir, Svedberg, Marie, Jia, Zhisheng, Krasikova, Raisa, Lemoine, Laetitia, Okamura, Nobujuki, Furumoto, Shozo, Mitsios, Nicholas, Mulder, Jan, Långström, Bengt, Nordberg, Agneta, Halldin, Christer, Stepanov, Vladimir, Svedberg, Marie, Jia, Zhisheng, Krasikova, Raisa, Lemoine, Laetitia, Okamura, Nobujuki, Furumoto, Shozo, Mitsios, Nicholas, Mulder, Jan, Långström, Bengt, Nordberg, Agneta, and Halldin, Christer

Abstract

Introduction: Due to the rise in the number of patients with dementia the imperative for finding new diagnostic and treatment options becomes ever more pressing. While significant progress has been made in PET imaging of A beta aggregates both in vitro and in vivo, options for imaging tau protein aggregates selectively are still limited. Based on the work previously published by researchers from the Tohoku University, Japan, that resulted in the development of [F-18]THK-5351, we have undertaken an effort to develop a carbon-11 version of the identical structure - [C-11]THK-5351. In parallel, THK-5351 was also labeled with tritium ([H-3]THK-5351) for use in in vitro autoradiography (ARG). Methods: The carbon -11 labeling was performed starting with di-protected enantiomeric pure precursor-tertbutyl 5-(6-( (2S)-3-fluoro-2-(tetrahydro-2H-Pyran-2-yloxy)proPoxy)quinolin-2-yl)pyridin-2-yl carbamate, which was reacted with [C-11]MeI, using DMF as the solvent and NaH as base, followed by deprotection with trifluoroacetic acid/water mixture, resulting in enantiomerically pure carbon-11 radioligand,[C-11]THK-5351 (S)-1-fluoro-3-(2-(6-([C-11]methylamino)pyridin-3-yl)quinolin-6-yloxy)propan-2-ol. Tritium labeling and purification of [H-3]THK-5351 were undertaken using similar approach, resulting in [H-3]THK-5351 with RCP >99.8% and specific radioactivity of 13 GB q/mu mol. Results: [C-11]THK-5351 was produced in good yield (1900 +/- 355 MBq), specific radioactivity (SRA) (361 +/- 119 GBq/mu rnol at EOS + 20 min) and radiochemical purity (RCP) (>99.8%), with enantiomeric purity of 98.7%. [H-3]TM-5351 was evaluated for ARG of tau binding in post-mortem human brain tissue using cortical sections from one AD patient and one control subject. [H-3]THK-5351 binding density was higher in the AD patient compared to the control subject, the binding was displaced by unlabeled THK-5351 confirming specific [H-3] THK-5351 binding. (C) 2016 Elsevier Inc. All rights reserved.

Published
2017
Full Text
View/download PDF

49. Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand

Author

Arakawa, Yuma, primary, Nai, YingHwey, additional, Shidahara, Miho, additional, Furumoto, Shozo, additional, Seki, Chie, additional, Okamura, Nobuyuki, additional, Tashiro, Manabu, additional, Kudo, Yukitsuka, additional, Yanai, Kazuhiko, additional, Gonda, Kohsuke, additional, and Watabe, Hiroshi, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results